UroGen Pharma Ltd. Net Income (Loss) Available to Common Stockholders, Basic
UroGen Pharma Ltd. (URGN) reported Net Income (Loss) Available to Common Stockholders, Basic of -$128.48 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-18.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2021-03-18
- UroGen Pharma Ltd. net income (loss) available to common stockholders, basic for the quarter ending 2018-12-31 was -$23.72M.
- UroGen Pharma Ltd. net income (loss) available to common stockholders, basic for the quarter ending 2018-09-30 was -$20.53M.
- UroGen Pharma Ltd. net income (loss) available to common stockholders, basic for the quarter ending 2018-06-30 was -$18.03M.
- UroGen Pharma Ltd. net income (loss) available to common stockholders, basic for the quarter ending 2018-03-31 was -$13.38M.
- UroGen Pharma Ltd. net income (loss) available to common stockholders, basic for fiscal 2020 was -$128.48M.
- UroGen Pharma Ltd. net income (loss) available to common stockholders, basic for fiscal 2019 was -$105.15M.
- UroGen Pharma Ltd. net income (loss) available to common stockholders, basic for fiscal 2018 was -$75.66M.
- UroGen Pharma Ltd. net income (loss) available to common stockholders, basic for fiscal 2017 was -$20.82M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$128.48M 10-K · filed 2021-03-18 | |||
| 2019-12-31 | -$105.15M 10-K · filed 2021-03-18 | |||
| 2018-12-31 | -$23.72M derived: 10-K 12 month − 6-K 9 month · filed 2020-03-02 | -$44.25M derived: sum of 2 quarters · filed 2020-03-02 | -$62.28M derived: sum of 3 quarters · filed 2020-03-02 | -$75.66M 10-K · filed 2020-03-02 |
| 2018-09-30 | -$20.53M 6-K · filed 2018-11-13 | -$38.56M derived: sum of 2 quarters · filed 2018-11-13 | -$51.94M 6-K · filed 2018-11-13 | -$62.03M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$18.03M 6-K · filed 2018-08-14 | -$31.41M 6-K · filed 2018-08-14 | -$41.49M derived: sum of 3 quarters · filed 2020-03-02 | -$41.79M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$13.38M 6-K · filed 2018-05-15 | -$23.47M derived: sum of 2 quarters · filed 2020-03-02 | -$23.77M derived: sum of 3 quarters · filed 2020-03-02 | -$30.18M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | -$10.09M derived: 10-K 12 month − 6-K 9 month · filed 2020-03-02 | -$10.38M derived: sum of 2 quarters · filed 2020-03-02 | -$16.80M derived: sum of 3 quarters · filed 2020-03-02 | -$20.82M 10-K · filed 2020-03-02 |
| 2017-09-30 | -$298.00K 6-K · filed 2018-11-13 | -$6.71M derived: sum of 2 quarters · filed 2018-11-13 | -$10.74M 6-K · filed 2018-11-13 | |
| 2017-06-30 | -$6.42M 6-K · filed 2018-08-14 | -$10.44M 6-K · filed 2018-08-14 | ||
| 2017-03-31 | -$4.02M 6-K · filed 2018-05-15 | |||
| 2016-12-31 | -$4.41M 10-K · filed 2019-02-28 | |||
| 2015-12-31 | -$13.54M 20-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |